New diabetes combo drug shows promise in early trial
NCT ID NCT00971243
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested four different doses of a new drug called MP-513 in 448 adults with type 2 diabetes who were already taking metformin. The goal was to see which dose works best and is safe for lowering blood sugar over 24 weeks, with an extension up to 52 weeks. Participants took MP-513 tablets once daily alongside their usual metformin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MP-513 (a diabetes drug) plus metformin
What this could lead to
If successful, this could provide a new treatment option for people with type 2 diabetes to better control their blood sugar when metformin alone isn't enough.
What could go wrong
This is an early phase II dose-finding study, so the drug may not prove effective or safe enough for approval. Side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Aalborg, Denmark
-
Study site
Ballerup Municipality, Denmark
-
Study site
Vejle, Denmark
-
Study site
Falkensee, Germany
-
Study site
Hamburg, Germany
-
Study site
Karlsruhe, Germany
-
Study site
Kiel, Germany
-
Study site
Ludwigshafen, Germany
-
Study site
Lübeck, Germany
-
Study site
Mainz, Germany
-
Study site
Ádám, Hungary
-
Study site
Békéscsaba, Hungary
-
Study site
Budapest, Hungary
-
Study site
Gyöngyös, Hungary
-
Study site
Kaposvár, Hungary
-
Study site
Miskolc, Hungary
-
Study site
Nyíregyháza, Hungary
-
Study site
Semmelweis, Hungary
-
Study site
Szentes, Hungary
-
Study site
Szigetvár, Hungary
-
Study site
Kaunas, Lithuania
-
Study site
Klaipėda, Lithuania
-
Study site
Vilnius, Lithuania
-
Study site
Gdansk, Poland
-
Study site
Krakow, Poland
-
Study site
Leszno, Poland
-
Study site
Lodz, Poland
-
Study site
Niemodlin, Poland
-
Study site
Płock, Poland
-
Study site
Warsaw, Poland
-
Study site
Wroclaw, Poland
-
Study site
Brasov, Romania
-
Study site
Bucharest, Romania
-
Study site
Galati, Romania
-
Study site
Ploieşti, Romania
-
Study site
Timișoara, Romania
-
Study site
Timuș, Romania
-
Study site
Addlestone, United Kingdom
-
Study site
Ayr, United Kingdom
-
Study site
Bournemouth, United Kingdom
-
Study site
East Sussex, United Kingdom
-
Study site
Edinburgh, United Kingdom
-
Study site
Oldham, United Kingdom
-
Study site
York, United Kingdom